These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16047540)

  • 1. Molecular aspects of thrombosis and antithrombotic drugs.
    Wu KK; Matijevic-Aleksic N
    Crit Rev Clin Lab Sci; 2005; 42(3):249-77. PubMed ID: 16047540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized antithrombotic therapy.
    Lüscher TF; Steffel J
    Hamostaseologie; 2016; 36(1):26-32. PubMed ID: 25597592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An antithrombotic therapy from the viewpoint of hematology].
    Asakura H
    Brain Nerve; 2015 Jan; 67(1):83-91. PubMed ID: 25585437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.
    Bird JE; Giancarli MR; Allegretto N; Barbera F; Wong P; Schumacher WA; Ogletree ML; Seiffert D
    Thromb Res; 2008; 123(1):146-58. PubMed ID: 18479740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
    Rukshin V; Shah PK; Cercek B; Finkelstein A; Tsang V; Kaul S
    Circulation; 2002 Apr; 105(16):1970-5. PubMed ID: 11997285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The new antithrombotic agents].
    Meyer Samama M
    Presse Med; 2005 Oct; 34(18):1309-14. PubMed ID: 16269995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
    Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative prophylactic antithrombotic strategies in vascular surgery: current practice in the Netherlands.
    Wiersema A; Bruijninckx C; Reijnen M; Vos J; Van Delden O; Vahl A; Zeebregts C; Moll F
    J Cardiovasc Surg (Torino); 2015 Feb; 56(1):119-25. PubMed ID: 23337406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current perspectives in the treatment of thrombotic disorders.
    Drouet L; Caen JP
    Semin Thromb Hemost; 1989 Apr; 15(2):111-22. PubMed ID: 2665082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
    Weisshaar S; Litschauer B; Gouya G; Mayer P; Smerda L; Kapiotis S; Kyrle PA; Eichinger S; Wolzt M
    J Thromb Haemost; 2014 Nov; 12(11):1850-60. PubMed ID: 25211369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of deep vein thrombosis. When to use which substance?].
    Bauersachs RM
    Internist (Berl); 2004 Dec; 45(12):1345-55. PubMed ID: 15517122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New targets for antithrombotic drugs.
    Thiagarajan P
    Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of thrombotic and cardiovascular disorders in the new millenium.
    Fareed J; Hoppensteadt DA; Bick RL
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic and Antiplatelet Drug Toxicity.
    Liss DB; Mullins ME
    Crit Care Clin; 2021 Jul; 37(3):591-604. PubMed ID: 34053708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Platelets and arterial thrombosis].
    Cazenave JP; Gachet C; Lanza F; Wiesel ML
    Bull Acad Natl Med; 2003; 187(1):35-44; discussion 45-6. PubMed ID: 14556452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
    Chesebro JH; Webster MW; Zoldhelyi P; Roche PC; Badimon L; Badimon JJ
    Circulation; 1992 Dec; 86(6 Suppl):III100-10. PubMed ID: 1424043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in antithrombotic agents.
    Chakrabarti R; Das SK
    Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):175-85. PubMed ID: 17630943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy].
    Nowak-Göttl U; Langer F; Limperger V; Mesters R; Trappe RU
    Dtsch Med Wochenschr; 2014 Jun; 139(24):1301-6. PubMed ID: 24892468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.